The present invention encompasses compounds of the formula (I)
wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
The present invention provides a compound of Formula III:
wherein A is:
and Z, R
1
, R
2
, R
3
, and R
4
are as defined herein, or a pharmaceutically acceptable salt thereof.
Fused Heterocyclic Compounds as Ion Channel Modulators
申请人:Kobayashi Tetsuya
公开号:US20120010192A1
公开(公告)日:2012-01-12
The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I:
wherein R
1
, R
2
, R
3
, R
4
, and R
5
are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to methods of using these compounds for the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.
The relative reactivity of olefins was determined in the homogeneous reaction with zinc carbenoid generated from diethylzinc and CH2I2. The Hammett ϱ-value for substituted styrenes in this reaction was −1·61. The inductive effect was concluded to be the most influential factor which determines the relative reactivity of olefins in the reaction. The mechanism of the reaction is discussed in comparison
在与由二乙基锌和CH 2 I 2生成的锌类胡萝卜素的均相反应中确定烯烃的相对反应性。该反应中取代苯乙烯的Hammett ϱ值为-1·61。结论是诱导作用是决定反应中烯烃相对反应性的最重要因素。与其他卡宾和类胡萝卜素反应相比,讨论了该反应的机理。